SynthesisBMC public health2023
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.
Synthesis in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07119957 (ProspEXPO), which is not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Clinical outcomes of early versus standard liver transplantation in patients with alcohol-related liver disease: a meta-analysis.Langenbeck's archives of surgery · 2026Pooled it
- Pooled it
- Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol-related liver disease: Findings from a pilot randomized controlled trial.Alcohol, clinical & experimental research · 2025Trial
- Training hepatologists in alcohol use disorder management: a pilot study.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Association Between Metabolic Obesity Phenotypes and Alcohol-Associated Fatty Liver Disease Among US Adults: A NHANES 2013-2018 Analysis.Journal of clinical medicine · 2026Article
- Fecal Microbiota Transplantation Is Associated with Better Survival Compared to Standard of Care in Severe Alcoholic Hepatitis Not Responding to Corticosteroids: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Multiplexed targeted mRNA profiling of alcohol-related liver disease reveals stage-specific dysregulation of signaling pathways.Molecular biology reports · 2026Article
- Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study.Hepatology (Baltimore, Md.) · 2026Observational
- Provider attitudes, practices, and barriers in alcohol-associated liver disease care: Findings from the CASL ALD SIG national survey.Canadian liver journal · 2026Article
- The Effect of Viniferin on Liver Cancer: Research Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulation.Medical sciences (Basel, Switzerland) · 2026Article
- A Novel ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder: Preclinical Findings.Cells · 2026Article
- LC-Pred: A Transformer-Based Interactive Interface for Liver Cirrhosis Prediction.International journal of hepatology · 2026Article
- Alcohol-related cirrhosis mortality, 1990-2021: temporal trends and development-level inequalities.Gastroenterology and hepatology from bed to bench · 2026Article
- Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study.Gastro hep advances · 2026Article
- Metabolic syndrome is independently associated with 1-year readmission in patients with alcohol-associated cirrhosis.Frontiers in medicine · 2026Article
- LivSCP: Improving Liver Fibrosis Classification Through Supervised Contrastive Pretraining.Diagnostics (Basel, Switzerland) · 2025Article
- Optimized acquisition for simultaneous intravoxel incoherent motion and RMagnetic resonance in medicine · 2025Article
- Evidence that extracellular HSPB1 contributes to inflammation in alcohol-associated hepatitis.Hepatology communications · 2025Article
- Increased 30-day mortality associated with weekend emergency admission for alcohol-related liver disease in England: a record-linkage study using the Clinical Practice Research Datalink.BMJ open gastroenterology · 2025Article
- How does taxation affect liver cirrhosis across age groups? An analysis of alcohol control policies on liver cirrhosis outcomes in Lithuania between 2001 and 2022.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol related liver disease (ARLD) is one of the major chronic liver diseases worldwide. This review aimed to describe the global prevalence, incidence, and outcomes of ARLD.
methodsMedline, Embase, The Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched from inception to May 31, 2022. The language was restricted to English or Chinese. According to the criteria, articles describing the basic characteristics of the population were selected. Two reviewers extracted the data independently.
resultsA total of 372 studies were identified: 353 were used for prevalence analysis, 7 were used for incidence analysis, and 114 were used to for outcome analysis. The prevalence of ARLD worldwide was 4.8%. The prevalence in males was 2.9%, which was higher than female (0.5%). Among the ethnic groups, the percentage was highest in Caucasians (68.9%). Alcoholic liver cirrhosis comprised the highest proportion in the disease spectrum of ARLD at 32.9%. The prevalence of ascites in ARLD population was highest (25.1%). The ARLD population who drinking for > 20 years accounted for 54.8%, and the average daily alcohol intake was 146.6 g/d. About 59.5% of ARLD patients were current or former smokers, and 18.7% were complicated with hepatitis virus infection. The incidence was 0.208/1000 person-years. The overall mortality was 23.9%, and the liver-related mortality was 21.6%.
conclusionThe global prevalence of ARLD was 4.8% and was affected by sex, region, drinking years, and other factors. Therefore, removing the factors causing a high disease prevalence is an urgent requisite.
trial registrationPROSPERO Nr: CRD42021286192.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.